Richard I. Fisher

Richard I. Fisher's AcademicInfluence.com Rankings

Richard I. Fisher

Engineering

#3131

World Rank

#4157

Historical Rank

Biomedical Engineering

#123

World Rank

#125

Historical Rank

engineering Degrees

Richard I. Fisher

Philosophy

#4574

World Rank

#7146

Historical Rank

Logic

#1986

World Rank

#2875

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Richard I. Fisher's Degrees

Doctorate Medicine Stanford University

Why Is Richard I. Fisher Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard I. Fisher's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
Revised response criteria for malignant lymphoma. (2007) (4137)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. (1999) (3170)
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. (2002) (2370)
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. (1993) (2215)
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. (1999) (1879)
Stromal gene signatures in large-B-cell lymphomas. (2008) (1611)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma (2010) (1436)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. (2004) (1410)
Oncogenically active MYD88 mutations in human lymphoma (2011) (1341)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. (2006) (1256)
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (1995) (1249)
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) (1153)
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003) (1074)
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. (1998) (975)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways (2008) (971)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. (2003) (948)
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. (1990) (905)
Molecular diagnosis of Burkitt's lymphoma. (2006) (871)
Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma (2008) (828)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (766)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) (706)
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. (2010) (692)
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. (2010) (656)
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. (2006) (534)
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. (2003) (461)
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. (2000) (449)
Thromboembolism in hospitalized neutropenic cancer patients. (2004) (447)
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. (2001) (432)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. (2005) (400)
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. (1983) (379)
New treatment options have changed the survival of patients with follicular lymphoma. (2005) (378)
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. (1995) (364)
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. (2010) (349)
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. (1988) (347)
Head and Neck Squamous Cell Carcinoma (2020) (336)
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. (1989) (333)
A War on Two Fronts: Cancer Care in the Time of COVID-19 (2020) (328)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. (2009) (322)
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. (2004) (317)
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. (1978) (303)
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. (2004) (295)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. (2006) (286)
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. (2013) (283)
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. (2006) (266)
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. (2008) (252)
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). (2005) (251)
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. (2012) (248)
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. (2005) (246)
Aggressive treatment for postcardiac transplant lymphoproliferation. (1995) (243)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. (2007) (243)
The epidemiology of non-Hodgkin's lymphoma (2004) (230)
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. (1977) (228)
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. (1989) (227)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. (2016) (224)
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. (1991) (217)
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. (1979) (217)
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. (1998) (212)
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. (1993) (207)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. (2001) (202)
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. (2009) (201)
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma (2007) (199)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
Association of the human type C retrovirus with a subset of adult T-cell cancers. (1983) (197)
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. (1993) (197)
ŒSTROGEN RECEPTORS IN HUMAN MALIGNANT MELANOMA (1976) (196)
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. (2012) (189)
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. (1993) (183)
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. (2007) (182)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. (2011) (180)
Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. (1987) (173)
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. (2002) (171)
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. (1981) (171)
Meta-analysis to evaluate the role of interferon in follicular lymphoma. (2005) (171)
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. (1993) (168)
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. (2003) (162)
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. (2013) (159)
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. (1996) (158)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. (2009) (155)
The human T-cell leukemia-lymphoma virus in the southeastern United States. (1983) (155)
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. (2015) (155)
Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. (1979) (152)
Lymphoma classification--the gap between biology and clinical management is closing. (1996) (148)
Diversity of immunological phenotypes of lymphoblastic lymphoma. (1983) (147)
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent (2005) (142)
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. (2001) (138)
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. (2013) (137)
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. (2020) (137)
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. (2013) (136)
Non-Hodgkin's lymphomas, version 4.2014. (2014) (131)
CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. (1994) (128)
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. (2016) (127)
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. (1980) (126)
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. (2013) (124)
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. (1989) (123)
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. (1998) (122)
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. (1994) (121)
Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. (2005) (120)
Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder (2008) (120)
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. (1988) (119)
The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia. (1983) (119)
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. (2013) (119)
N2‐N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—Results of Trans Tasman Radiation Oncology Group Study 98.02 (2008) (118)
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. (2010) (115)
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. (1994) (115)
Diffuse large-cell lymphoma. (2000) (110)
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial (2014) (108)
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. (2001) (108)
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. (2015) (107)
Prolonged initial remission in patients with nodular mixed lymphoma. (1984) (103)
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. (1991) (103)
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 (2013) (103)
Diffuse histiocytic lymphoma involving the gastrointestinal tract (1978) (102)
Diffuse aggressive lymphoma. (2004) (102)
Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. (1987) (101)
Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 (2016) (101)
High-dose aldesleukin in renal cell carcinoma: long-term survival update. (1997) (99)
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 (2009) (96)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. (2011) (96)
Measurement of lung tumor volumes using three-dimensional computer planning software. (2002) (95)
Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features. (1976) (94)
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. (1998) (94)
A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. (1981) (92)
In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. (1988) (92)
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. (2003) (91)
Immunologic phenotypes of diffuse, aggressive, non‐Hodgkin's lymphomas. Correlation with clinical features (1984) (90)
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI) (2010) (89)
The impact of Hodgkin's disease on the immune system. (1990) (88)
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. (2000) (87)
The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib (2013) (86)
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. (1990) (85)
Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma (2011) (84)
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). (2003) (84)
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. (1997) (83)
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. (2019) (82)
Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma (2009) (81)
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas (2009) (79)
Venous thromboembolism in patients with diffuse large B-cell lymphoma (2006) (79)
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma (2013) (77)
Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. (1989) (77)
Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. (1999) (76)
Diffuse Large B-Cell Lymphoma Version 1.2016. (2016) (76)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. (2005) (75)
Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma (1978) (74)
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. (1987) (72)
Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. (1986) (71)
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 (2012) (70)
Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. (1983) (69)
Diffuse large B-cell lymphoma. (2008) (69)
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. (1997) (69)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. (2001) (69)
Effects of interleukin 2 on cardiac function in the isolated rat heart. (1990) (68)
Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. (1989) (68)
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. (1981) (68)
Leukemic transformation in polycythemia vera: Analysis of risk factors (1990) (67)
An outbreak of varicella-zoster virus infection among cancer patients. (1980) (66)
Neurotoxicity associated with systemic high-dose cytosine arabinoside. (1986) (66)
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. (1977) (65)
A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma. (2007) (63)
Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. (1985) (63)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone (2012) (63)
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. (1994) (62)
Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. (1989) (62)
Peritoneoscopy in the management of ovarian cancer. (1981) (62)
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). (2010) (60)
Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2011) (60)
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma (1978) (59)
IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells. (1995) (59)
1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. (1989) (59)
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. (2012) (58)
A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. (1989) (58)
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. (2019) (57)
Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. (2004) (57)
Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma (2012) (57)
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases. (1984) (57)
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. (2001) (57)
Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. (1988) (57)
Staging of non-Hodgkin's lymphoma. (1980) (56)
Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (55)
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. (1990) (55)
Effects of interleukin-2 immunotherapy on renal function. (1988) (55)
m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. (1990) (55)
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. (2003) (54)
Natural history of malignant lymphomas with divergent histologies at staging evaluation (1981) (53)
Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. (1994) (53)
Oestrogen receptors in human malignant melanoma. (1976) (52)
Current trends in large cell lymphoma (2003) (52)
Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. (1982) (52)
Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. (1979) (52)
Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. (2003) (51)
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (2011) (51)
Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study (2014) (50)
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. (2003) (50)
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. (2018) (50)
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. (2010) (49)
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
Follicular lymphomas: do histologic subtypes predict outcome? (1997) (48)
Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. (1992) (48)
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma (2005) (47)
Biochemical and structural properties of a Hodgkin's disease-related membrane protein. (1988) (47)
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial (2011) (47)
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. (1989) (47)
Novel therapeutics for aggressive non-Hodgkin's lymphoma. (2011) (47)
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines (2017) (47)
Non-Hodgkin's lymphomas, version 2.2014. (2014) (46)
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. (2015) (46)
Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. (1995) (45)
BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. (1998) (45)
Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. (1991) (45)
Characterization of the lymphocyte surface receptors for Con A and PHA. (1975) (44)
Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals. (1991) (43)
Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. (2009) (42)
A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. (1994) (42)
Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 (2005) (42)
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. (2009) (42)
Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). (2004) (41)
FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy (2003) (41)
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. (1994) (41)
Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). (2009) (41)
Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations. (1982) (41)
Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. (2007) (40)
Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601 (2016) (40)
A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial (2019) (39)
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. (1993) (39)
Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). (2017) (39)
EOE-13 in the detection of hepatosplenic lymphoma. (1982) (38)
Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study. (2021) (38)
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. (2008) (37)
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. (2020) (37)
Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma (2008) (37)
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. (1994) (37)
BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress (2009) (37)
Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). (2009) (36)
The Role of Bortezomib in the Treatment of Lymphoma (2007) (36)
The Complex Relationship Between Lung Tumor Volume and Survival in Patients with Non-Small Cell Lung Cancer Treated by Definitive Radiotherapy: a Prospective, Observational Prognostic Factor Study of the Trans-Tasman Radiation Oncology Group (Trog 99.05) (2012) (36)
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2013) (36)
RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106 (2017) (36)
Multiple recurrences of acute tumor lysis syndrome in an indolent non‐hodgkin's lymphoma (1985) (35)
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas (2018) (35)
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin. (1979) (35)
Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma (1978) (35)
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. (1997) (35)
Advances in the staging and treatment of ovarian cancer (1977) (34)
Antigen presentation by Hodgkin's disease cells. (1985) (34)
A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. (1981) (34)
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. (1997) (33)
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab (2013) (33)
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. (2001) (33)
Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses. (1984) (32)
Correlation of p16 status, hypoxic imaging using [18F]‐misonidazole positron emission tomography and outcome in patients with loco‐regionally advanced head and neck cancer (2014) (32)
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial (2010) (32)
Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen. (1980) (32)
Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma (2004) (32)
A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma (1994) (32)
A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2 (2014) (31)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. (1993) (31)
Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients? (2006) (31)
Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo (2012) (30)
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. (2010) (30)
Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494 (2010) (30)
A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806 (2018) (30)
Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517. (2007) (30)
Bleomycin in non-Hodgkin's lymphoma. (1992) (29)
An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. (1990) (28)
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. (2014) (28)
Treatment of aggressive non‐hodgkin's lymphomas: Lessons from the past 10 years (1994) (28)
Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (28)
Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. (2010) (28)
Stage Is Not a Reliable Indicator of Tumor Volume in Non-small Cell Lung Cancer: A Preliminary Analysis of the Trans-Tasman Radiation Oncology Group 99-05 Database (2006) (28)
Receptors for steroid hormones in human melanoma. (1976) (27)
R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433 (2014) (27)
Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance. (1982) (27)
Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (2008) (27)
Regression of a T-cell lymphoma after administration of antithymocyte globulin. (1978) (26)
Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease. (1982) (26)
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. (1998) (26)
A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes (1994) (26)
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma (1997) (26)
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. (2017) (25)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study (2005) (25)
The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications (2006) (25)
A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 (2003) (25)
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520 (2016) (25)
Mantle-cell lymphoma: classification and therapeutic implications. (1996) (24)
Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial (2000) (23)
Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. (2005) (23)
Immunology and cellular biology of Hodgkin's disease. (1989) (23)
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. (1991) (22)
Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity. (2002) (22)
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. (1991) (21)
Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. (2007) (21)
Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma (2014) (21)
Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function. (1979) (21)
Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer. (1981) (21)
Diethylstilbestrol therapy of surgically non-resectable malignant melanoma (1978) (20)
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. (1996) (20)
Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update (2007) (20)
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. (1981) (19)
Adjuvant Radiotherapy Improves Regional (Lymph Node Field) Control in Melanoma Patients after Lymphadenectomy (2009) (19)
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWO (2006) (19)
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. (2005) (19)
A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma (2011) (18)
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas (2016) (18)
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. (2007) (18)
A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. (1994) (17)
Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma. (1991) (17)
Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkin's disease. (1981) (17)
Decreased Expression of Class II Major Histocompatibility Antigens on Monocytes From Patients With Hodgkin's Disease (1986) (17)
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. (2015) (17)
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. (1985) (17)
3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04) (2007) (16)
Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin. (1982) (15)
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494) (2017) (15)
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study (1994) (15)
Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) (2008) (15)
Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma. (2000) (15)
Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). (2013) (15)
Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. (1992) (14)
Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL). (2006) (14)
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (2017) (14)
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. (2001) (14)
R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793 (2010) (14)
Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER AND OKT3. REPLY (1991) (14)
Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800). (2004) (14)
A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. (1997) (14)
Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. (2006) (14)
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. (1988) (13)
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 (2019) (13)
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. (2014) (13)
Clinical practice guidelines: non-Hodgkin's lymphomas. (1995) (12)
The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells. (2005) (12)
Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work). (2004) (12)
Increased sensitivity of lymphocytes from patients with Hodgkin's disease to concanavalin A-induced suppressor cells. (1981) (12)
A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer. (2019) (12)
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. (2018) (12)
New REAL clinical entities. (1998) (11)
Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. (1992) (11)
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. (2012) (11)
Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. (1992) (11)
Percutaneous aspiration of retroperitoneal lymph nodes in ovarian cancer. (1980) (11)
The staging and treatment of epithelial ovarian cancer. (1978) (10)
Recommendations for revised response criteria for malignant lymphoma. (2006) (10)
Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601 (2014) (10)
Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers (2021) (10)
An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. (2005) (10)
Natural history of malignant melanoma as related to therapy. (1976) (10)
Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. (2009) (10)
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine. (2022) (10)
Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease. (1982) (10)
Treatment of grey zone lymphomas. (1998) (9)
Use of Intravenous Liposoluble Contrast Material for the Examination of the Liver and Spleen in Lymphoma (1981) (9)
Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494). (2004) (9)
A Phase IA/IB Trial of Anti‐CD3 Murine Monoclonal Antibody plus Low‐Dose Continuous‐Infusion Interleukin‐2 in Advanced Cancer Patients (1995) (9)
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). (2014) (9)
Non-Hodgkin's lymphomas after treatment of Hodgkin's disease. (1983) (9)
Long-term Quality of Life in patients treated in TROG 01.04: a randomized trial comparing short course and long course preoperative radiation therapy for rectal cancer (2012) (9)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. (2003) (9)
New Treatment Options Have Changed the Natural History of Follicular Lymphoma. (2004) (9)
Diffuse large B-cell NHL. (2006) (8)
Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity. (1988) (8)
Expression of VEGF, VEGF Receptors, and Other Angiogenic Markers in Relapsed Aggressive Non-Hodgkin’s Lymphoma : Correlative Sudies from the SWOG S0108 Trial. (2004) (8)
Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515 (2010) (8)
A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. (2012) (8)
Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. (1979) (8)
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. (1998) (8)
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
Clinical verification of the superiority of the current International Union Against Cancer staging criteria in an Australian population of patients with nasopharyngeal carcinoma. (2004) (7)
Immunohistochemical Analyses for Potential Biomarkers of Bortezomib Activity in Mantle Cell Lymphoma from the PINNACLE Phase 2 Trial. (2007) (7)
Diffuse large-cell lymphomas: a review of therapy. (2001) (7)
'Boomerang' technique: an improved method for conformal treatment of locally advanced nasopharyngeal cancer. (2004) (7)
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496. (2011) (7)
Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkinʼs lymphomas: 166 (1994) (7)
Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma. (2009) (7)
Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas (2013) (7)
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (2019) (7)
Lack of histocompatibility antigens on a murine ovarian teratocarcinoma. (1981) (7)
Advanced insights into the biology of malignant lymphomas. (2011) (7)
A comparison of quality of life in patients with T3 rectal cancer receiving short course versus long course preoperative radiation. A Trans-Tasman Radiation Oncology Group Trial (TROG 01.04) (2008) (6)
Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapuetic regimens : Results from the international Burkitt lymphoma collaborative group (2005) (6)
Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. (2005) (6)
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 (2010) (6)
Report of workshop 5: early high-dose chemotherapy. (1996) (6)
Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study (1991) (6)
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? (1995) (6)
Comparison of nodal primary versus extranodal primary histiocytic lymphoma. (1977) (6)
Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016 (2018) (5)
Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial (2016) (5)
Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non‐Hodgkin's lymphomas (1984) (5)
Is observation dead in follicular lymphoma? No, but the apoptosis pathway has been activated. (2015) (5)
Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning (2004) (5)
The effectiveness of tositumomab and iodine I 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). (2004) (5)
Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
Treatment of diffuse large B-cell lymphomas. (2006) (5)
Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736. (2004) (5)
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma. (1990) (4)
A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas. (2007) (4)
Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. (2004) (4)
The role of myeloablation for lymphoma. (2014) (4)
SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987) (2014) (4)
Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma Lymphoma/Leukemia Molecular Profiling (2007) (4)
Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer. (2001) (4)
Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016 (2016) (4)
Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133. (2004) (4)
11 – Preclinical and Clinical Experiences with Drug Combinations Designed to Inhibit DNA Repair in Resistant Human Tumor Cells (1988) (4)
Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. (1982) (4)
CHOP therapy: has shorter-course therapy had an impact on lymphomas? (1998) (4)
Impact of Increased Body Weight on Acute Toxicity and Outcome of Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma: A Southwest Oncology Group Analysis. (2004) (4)
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials (2013) (4)
Increased risk of lymphoproliferative disorders following the use ofOKT3 in cardiac transplantation (1992) (4)
O-225 Tumor volume correlates poorly with disease stage in non-small cell lung cancer (NSCLC): preliminary analysis of the Trans-Tasman Radiation Oncology Group (TROG) 99-05 database (2003) (3)
Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life (2019) (3)
Prognostic Indices in Older DLBCL Patients Receiving R-CHOP: An Analysis of the U.S. Intergroup Study (E4494, CALGB 9793). (2006) (3)
ProMACE-MOPP combination chemotherapy for diffuse lymphomas. (1985) (3)
Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. (2005) (3)
Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo (2010) (3)
Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (2011) (3)
Support for a Possible Vaccinal Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab. (2007) (3)
Chemotherapy versus chemotherapy plus radiotherapy for stage IIIA, IIIB Hodgkin's disease. A southwest oncology group study (1979) (3)
Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
A phase II trial of preoperative radiotherapy with protracted infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A multi-center trial for the Trans-Tasman Radiation Oncology Group (2000) (3)
Adolescents with Hodgkin Lymphoma Treated on Adult and Pediatric Protocols Have Distinct Therapeutic Outcome. (2004) (3)
Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. (2005) (3)
In reply [11] (2007) (3)
Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study. (2007) (3)
Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine (2007) (3)
A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma (2020) (3)
Subtype-specific therapy for DLBCL: are we there yet? (2015) (3)
Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma. (2006) (3)
Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab (2012) (3)
Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin (LY317615) in Combination with Multiple Therapeutic Agents. (2008) (3)
Phase II Trial of Menogaril in Non-Hodgkin's Lymphomas: a Southwest Oncology Group Trial (2004) (3)
MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study (2008) (2)
A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial (2011) (2)
Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494 (2007) (2)
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208 (2017) (2)
Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting. (2001) (2)
Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project (2005) (2)
Delayed relapse following preoperative chemoradiation and surgery for rectal cancer (2003) (2)
CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment. (2005) (2)
Superiority of tirapazamine-containing chemoradiation in head and neck cancers showing evidence of hypoxia on 18F-misonidazole (FMISO) pet scanning. (2004) (2)
Does institutional patient accrual volume impact overall survival in patients with inoperable non‐small‐cell lung cancer receiving radical (chemo)radiation? A secondary analysis of TROG 99.05 (2020) (2)
Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (2010) (2)
Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). (2007) (2)
Reply to M.C. Chamberlain (2009) (2)
A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806 (2015) (2)
The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib. (2012) (2)
MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study (2012) (2)
Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL). (2006) (2)
Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02. (2012) (2)
Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin’s Lymphoma. (2004) (2)
Relapse after successful treatment with immunotherapy: lessons for the future. (1998) (2)
A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. (2012) (2)
Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. (2018) (2)
Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology (2014) (2)
Amonafide treatment of refractory esophageal cancer (1993) (2)
491 The prognostic significance of 18F-misonidazole (FMISO) PET-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with and without tirapazamine (2004) (2)
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas (2019) (2)
Markers of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab. (2013) (1)
Reply to G. Keramida et al. (2015) (1)
Real-World Application of National Comprehensive Cancer Network (NCCN) Testing Guidelines in Diffuse Large B-Cell Lymphoma (DLBCL) Results in Underdiagnosis of Double-Hit Lymphoma (2019) (1)
Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice. (1980) (1)
A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) (2017) (1)
Interclinician variation in lung tumour volume determination using a 3-D treatment planning system (2000) (1)
P-351 Is tumor volume an independent prognostic factor in non-smallcell lung cancer (NSCLC) treated with radical radiotherapy? Interim analysis of the Trans-Tasman Radiation Oncology Group (TROG) database 99-05 (2005) (1)
Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (2011) (1)
A clinical phase II study of ProMACE-CytaBOM. (1991) (1)
What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The “RAVES” phase III randomized clinical trial. (2012) (1)
Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo (2019) (1)
Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study (2011) (1)
Long-Term Follow-up of 153 Candidates for Definitive Radiation or Chemoradiation Therapy with Non-Small Cell Lung Cancer Who Were Staged by PET: Implications for Design of Future Randomized Trials (2005) (1)
The complex relationship of lung tumor volume to survival in patients with non-small cell lung cancer (NSCLC) treated by definitive radiotherapy (RT): (Trans Tasman Radiation Oncology Group Study 9905) (2009) (1)
High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era (2010) (1)
Chemotherapy and combined modality treatment in Hodgkin's disease (1991) (1)
Diffuse Small Noncleaved-Cell, Non-Burkitt's Lymphoma in Adults (2016) (1)
CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma. (2007) (1)
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma (2008) (1)
Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches? (2019) (1)
Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma (2011) (1)
Treatment options for recurrent lymphomas. (1990) (1)
Predictors of vitality (energy/fatigue) in early stage Hodgkin's disease (HD): Results from Southwest Oncology Group (SWOG) Study 9133 (2004) (1)
Expression of p 21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP : A Prospective ECOG and Southwest Oncology Group Correlative Study on E 4494 (2010) (1)
Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (2010) (1)
Identification of a Novel CD 56 Lymphokine-activated Killer Cell Precursor in Cancer Patients Receiving Recombinant Interleukin 2 ' (2006) (1)
Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphom (1991) (1)
The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage.. (2009) (1)
Treatment of diffuse large cell non-Hodgkin’s lymphomas (1985) (1)
Cancer Therapy : Preclinical Aurora A Inhibitor ( MLN 8237 ) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma (2012) (1)
Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45 (2012) (1)
Abstract 5366: The small molecule Bcl-2 antagonist obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC and ABC- sub types of DLBCL cells bothin vitroandin vivo (2011) (0)
Single-institution experience with autologous stem cell transplants for mantle cell lymphoma patients. (2014) (0)
High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. (2004) (0)
Disseminated Infection byFusariummoniliforme During Treatment forMalignant Lymphoma (1978) (0)
Randomized C omparison o f A BVD a nd M OPP/ABV H ybrid f or the T reatment o f A dvanced H odgkin's D isease: R eport o f a n Intergroup T rial (2003) (0)
Checkpoint inhibitor therapy, with and without radiation, in diffuse large B cell lymphoma: A single-center analysis. (2019) (0)
A novel high-dose chemotherapy regimen of cyclophosphamide, mitoxantrone, and carboplatin with autologous bone marrow transplantation: Activity in refractory gynecologic malignancies (1991) (0)
Early Stage Large B-cell Lymphoma in the Rituximab-CHOP +/- Radiation Era: Tailored Therapy Provides Excellent Outcome (2009) (0)
Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)
Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH. (2007) (0)
survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated (2013) (0)
Origin and biologic function of Reed-Sternberg cells (1985) (0)
Preclinical Development Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Car fi lzomib in GC-and ABC-DLBCL Cells In Vitro and In Vivo (2012) (0)
Recent advances in the management of non-Hodgkin's lymphomas. (1989) (0)
Controversy I : controversies in follicular lymphomas (2011) (0)
Prognostic Signi fi cance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02 . 02 Phase III Trial (2011) (0)
Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era. (2007) (0)
Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592) (2017) (0)
Malignant melanoma: prognostic factors and therapeutic results. (1977) (0)
Title Prognostic significance of plasma osteopontin in patients with loco-regionally advanced head and neck squamous cell carcinoma treated on TROG 02 . 02 Phase III trial (2011) (0)
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. (1991) (0)
75 Can hypoxia imaging be used to identify patients for tirapazamine-based therapy? (2006) (0)
Combination o f F ludarabine a nd M itoxantrone i n U ntreated Stages I II a nd I V L ow-Grade L ymphoma: S 9501 (2003) (0)
Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801 (2016) (0)
Detecting Clonal Evolution in CLL Patients Treated with Targeted Therapies Versus Chemotherapy Utilizing Cytogenetic Microarray Analysis (2018) (0)
QOL for Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial of Tirapazamine, Cisplatin, and Radiation vs. Cisplatin and Radiation (TROG 02.02) (2009) (0)
Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials. (2010) (0)
Lack of h-2 antigens on a murine ovarian carcinoma curable by immunotherapy. Abstr. (1980) (0)
Correction (2019) (0)
Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas (2010) (0)
High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993 (1999) (0)
Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis (2016) (0)
T cell receptor expression can switch on and off at a posttranslational level. (1992) (0)
Chapter 4 Molecular Diagnosis of Burkitt lymphoma (2019) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials. (2008) (0)
FDG-PET in lymphoma (2014) (0)
session 3 – biology and novel rational therapeutic targets in DLBCL (2008) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
Involved Field Radiation After Autologous Stem Cell Transplant for Large B-Cell Lymphoma in the R-CHOP Era (2007) (0)
Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology (2016) (0)
Health S tatus a nd Q uality o f L ife i n P atients W ith Early-Stage H odgkin's D isease T reated o n S outhwest O ncology Group S tudy 9 133 (2003) (0)
Question-and-Answer Forum (2005) (0)
Early Diagnosis, Treatment and Care of Cancer Patients (2008) (0)
University of Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (0)
diffuse, aggressive non-Hodgkin's lymphomas Prognostic implications of ploidy and proliferative activity in the (2011) (0)
Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma (2014) (0)
Predictor of survival Diffuse large B-cell lymphoma (2009) (0)
Long-term prospective assessment of quality of life and lymphedema after inguinal or inguinal and pelvic lymphadenectomy for recurrent melanoma in the groin (2016) (0)
Numbers of Lymphoma Associated Macrophages (LAMS) and Regulatory T-Cells (Tregs) in Follicular Lymphoma (FL) Patients (pts) Treated with and without Monoclonal Antibody (MoAb)-Containing Therapy Do Not Correlate with Overall Survival (OS): A Study from the Southwest Oncology Group (SWOG). (2007) (0)
Diffuse L arge B - Cell Lymphoma (2008) (0)
Chemotherapy of ovarian cancer. (1978) (0)
Phase II Study of Rituximab in Combinat ion With CHOP Chemotherapy in Pat ients With Prev ious ly Untreated , Aggress ive Non-Hodgkin ’ s Lymphoma (2000) (0)
lymphoma patients with relapsed/refractory indolent and mantle cell non-Hodgkin The combination of bendamustine, bortezomib, and rituximab for (2011) (0)
Prospective analysis of late toxicity from adjuvant post prostatectomy radiotherapy in the TROG 08.03 RAVES clinical trial (2014) (0)
Melanoma patients with durable responses to IL-2 treatment: role of surgical salvage for persistent or recurrent disease (1997) (0)
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2019) (0)
Prognostic and Predictive Signi fi cance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (0)
ABT199 and ONC201 in Diffuse Large B Cell Lymphoma Cell Lines (2015) (0)
Chlorozotocin, an antitumor agent producing lymphopenia without bone marrow toxicity. Abstr. (1977) (0)
POSTER: PHYSICS TRACK: IMPLEMENTATION OF TECHNOLOGY, TECHNIQUES, CLINICAL PROTOCOLS OR TRIALSPO-0877: QA for radiation therapy in a prospective head & neck study: Outcome impact of ICRs performed by the EORTC QART program (2013) (0)
Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study (2013) (0)
Picking winners and losers in diffuse small-cell lymphomas. (1989) (0)
Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project. (2009) (0)
l-/3-D-Arabinofuranosylcytosine and Hydroxyurea Production of Cytotoxic Synergy with cis-Diamminedichloroplatinum(II) and Modification of Platinum-induced DNA Interstrand Cross-Linking1 (2006) (0)
Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas. (2006) (0)
179: Allogeneic Stem Cell Transplantation for Post-Autologous Stem Cell Transplant Relapse in Hodgkin Lymphoma: Experience at a Single Center (2008) (0)
Cytoxan vepeside adriamycin methotrexate prednisone nitrogen mustard vincristine procarbazine prednisone combination chemo therapy treatment of diffuse lymphomas (1980) (0)
Central Nervous System (CNS) Relapse in Agressive Non-Hodgkin’s Lymphoma; Does CNS Prophylaxis Work?. (2007) (0)
Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016 (2019) (0)
Clinicopathologic Correlates of the REAL Classification (1998) (0)
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma (2016) (0)
Preclinical Development Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2011) (0)
Laboratory Study Cooperative Oncology Group and Southwest Oncology Group Cooperative Intermediate- and High-Grade Non-Hodgkin's Lymphomas: An Eastern BCL-2 Expression Correlates With Lower Proliferative Activity in the (2013) (0)
Diversity of Immunological Phenotypes of Lymphoblastic Lymphoma 1 (2006) (0)
Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?. (2007) (0)
‘ ‘ focus on . . . ’ ’ session : profiling and prognosis (2008) (0)
Clinical features and response to current treatment modalities in mantle cell lymphoma (1999) (0)
Clinical Evaluation and Management of Lymphoma (2011) (0)
126 Risk factors for febrile neutropemia among older patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) treated with anthracycline-based chemotherapy (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard I. Fisher?

Richard I. Fisher is affiliated with the following schools:

Richard I. Fisher's Academic­Influence.com Rankings

Richard I. Fisher's Degrees

Why Is Richard I. Fisher Influential?

Richard I. Fisher's Published Works

Published Works

What Schools Are Affiliated With Richard I. Fisher?

Richard I. Fisher's AcademicInfluence.com Rankings